Skip to main content
SpringerLink
Log in
Book cover

Toxoplasmosis pp 191–198Cite as

Toxoplasma Gondii: Chemotherapy

  • Conference paper

  • 164 Accesses

Part of the book series: NATO ASI Series ((ASIH,volume 78))

Abstract

Infection with Toxoplasma gondii is widespread and has been observed in man and in almost all warm-blooded animals. Most immunologically normal adults acutely infected with T. gondii present only self-limited symptoms and signs. This is in great contrast with the morbidity and mortality that is observed in children with congenital and acquired toxoplasmosis, and in immunocompromised patients, notably those affected by the acquired immune deficiency syndrome (AIDS). Prompt antimicrobial therapy is given to patients with the aim of inhibiting the replication of the parasite and to prevent or to reduce the tissue damage resulting from parasitic intracellular multiplication. This therapy, nevertheless, is inactive against the non-multiplying (extracellular) or metabolically inactive (cyst) form of the parasite. Therapy of toxoplasmosis is further complicated by the possibility of harmful effects of the drugs on the fetus during therapy of pregnant women infected for the first time with T. gondii. The high frequency of side effects observed in AIDS patients treated for toxoplasmic encephalitis may lead to withdrawal of therapy and this enhances the possibilities of recurrent disease. All these considerations, therefore, point out the need for safer alternatives in the therapy of toxoplasmosis.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, Masur H (1987) Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest 79: 478–482.

    Article  PubMed  CAS  Google Scholar 

  • Araujo FG, Remington JS, (1974) Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother 5: 647–651.

    PubMed  CAS  Google Scholar 

  • Araujo FG, Guptill DR, Remington JS (1987) In vivo activity of piritrexim against Toxoplasma gondii. J Inf Dis 156: 828–830.

    Article  CAS  Google Scholar 

  • Araujo FG, Guptill DR, Remington JS (1988) Azithromycin, amacrolide with potent activity against Toxoplasma gondii. Antimicrob Agents Chemother 32: 755–757.

    PubMed  CAS  Google Scholar 

  • Araujo FG, Huskinson J, Remington JS (1991) Remarkable in vitro and in vivo activities of the hydroxynaphtoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother 35: 293–299.

    PubMed  CAS  Google Scholar 

  • Araujo FG, Huskinson-Mark J, Gutteridge WE, Remington JS (1992) In vitro and in vivo activities of the hydroxynapthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother 36: 326–330.

    PubMed  CAS  Google Scholar 

  • Chan J, Luft BJ (1986) Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice. Antimicrob Agents Chemother 30: 323–324.

    PubMed  CAS  Google Scholar 

  • Chang HR, Pechere JCF (1987) Effect of roxithromycin on acute toxoplasmosis in mice. 31: 1147–1149.

    CAS  Google Scholar 

  • Chang HR, Pechere JC (1988a) In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. Antimicrob Agents Chemother 32:524–529.

    Google Scholar 

  • Chang HR, Pechere JC (1988b) Arteether, a qinghaosu derivative in toxoplasmosis. Trans Roy Soc Trop Med Hyg 82: 867.

    Article  PubMed  CAS  Google Scholar 

  • Chang HR, Rudareanu FC, Pechere JC (1988) Activity of A-56268 (TE-031), a new macrolide against Toxoplasma gondii in mice. J Antimicrob Agents Chemother 22: 359–361.

    Article  CAS  Google Scholar 

  • Chang HR, Jefford CW, Pechere JC (1989) In vitro effects of three new 1,2,4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii. Antimierob Agents Chemother 33: 1748–1752.

    CAS  Google Scholar 

  • Chang HR, Comte R, Pechere JC (1990) In vitro and in vivo effects of doxycycline on Toxoplasma gondii. Antimierob Agents Chemother 34:775–780.

    Google Scholar 

  • Chang HR, Grau GE, Pechere JC (1990) Role of TNF and IL-1 infections with Toxoplasma gondii. Immunology 69: 33–37.

    PubMed  CAS  Google Scholar 

  • Chang HR, Comte R, Piguet PF, Pechere JC (1991) Activity of minocycline against Toxoplasma gondii in mice. J Antimierob Chemother 27: 639–645.

    Article  CAS  Google Scholar 

  • Chang HR, Pechere JC, Piguet PF (1992) Role of tumour necrosis factor in murine chronic toxoplasmic Toxoplasma gondii encephalitis. Immunol Infect Dis 2: 61–68.

    Google Scholar 

  • Freund YR, Slargato G, Jacob CO, Suzuki Y, Remington JS (1992) Polymorphisms in tumor necrosis factor α ( TNF- α) gene correlate with murine resistance to development of toxoplasmic encephalitis and with levels of TNF-a mRNA in infected brain tissue. J Exp Med 175: 683–688.

    Article  PubMed  CAS  Google Scholar 

  • Harris C, Salgo MP, Tanowitz HB, Wittner M (1988) In vitro assessment of antimicrobial agents against Toxoplasma gondii. J Infect Dis 157: 14–22.

    Article  PubMed  CAS  Google Scholar 

  • Huskinson-Mark J, Araujo FG, Remington JS (1991) Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis 164: 170–177.

    Article  PubMed  CAS  Google Scholar 

  • Israelski D, Remington JS (1991) Activity of γ interferon in combination with pyrimethamine or clindamycin in the treatment of murine toxoplasmosis. Eur J Clin Microbiol Infect Dis 9: 358–360.

    Article  Google Scholar 

  • Kovacs JA, Allegra CJ, Swan JC, Drake J, Parrillo JE, Chabner BA, Masur H (1988) Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrob Agents Chemother 32: 430–433.

    PubMed  CAS  Google Scholar 

  • Krug EC, Man JJ, Berens RL (1989) Purine metabolism in Toxoplasma gondii. J Biol Chem 264: 10601–10807.

    PubMed  CAS  Google Scholar 

  • Luft BJ (1986) Potent in vivo activity of arprinocid, a purine analogue, against murine toxoplasmosis. J Infect Dis 154: 692–694.

    Article  PubMed  CAS  Google Scholar 

  • McCabe RE, Luft BJ, Remington JS (1984) Effect of murine interferon γ in toxoplasmosis. J Infect Dis 150: 961–962.

    Article  PubMed  CAS  Google Scholar 

  • Ou-Yang K, Krug EC, Marr JJ, Berens RL (1990) Inhibition of growth of Toxoplasma gondii by qinghaosu and derivatives. Antimierob Agents Chemother 34: 1961–1965.

    Google Scholar 

  • Pfefferkorn ER (1978) Toxoplasma gondii: the enzymic defect of a mutant resistant to 5-fluorodeoxyuridine. Exp Parasitol 44:26–35.

    Google Scholar 

  • Pfefferkorn ER, Pfeiferkorn LC (1977) Specific labeling of intracellular Toxoplasma gondii with uracil. J Protozool 24: 449–453.

    PubMed  CAS  Google Scholar 

  • Pfefferkorn ER, Pfefferkorn LC (1978) The biochemical basis for resistance to adenine arabinoside in a mutant of T. gondii. J Parasitol 64: 488–492.

    Article  Google Scholar 

  • Pfefferkorn ER, Eckel ME, McAdams E (1988) Toxoplasma gondii: in vitro and in vivo studies with a mutant resistant to arprinocid-N-oxide. Exp Parasitol 65: 282–289.

    Article  PubMed  CAS  Google Scholar 

  • Pfefferkorn ER, Eckel ME, McAdams E (1989) Toxoplasma gondii: the biochemical basis of resistance to emimycin. Exp Parasitol 69: 129–139.

    Article  PubMed  CAS  Google Scholar 

  • Summers WA (1949) The effects of oral administration of aureomycin, sulfathiazole, sulfamerazine, and 4,4-diaminodiphenylsulfone on toxoplasmosis in mice. Am er J Trop Med 29: 889–893.

    CAS  Google Scholar 

  • Tabbara KF, Sakuragi S, O’Connor GR (1982) Minocycline in the chemotherapy of murine toxoplasmosis. Parasitology 84: 297–302.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Hernan R. Chang MB, MD, Dr Med

    Present address: Department of Microbiology, Faculty of Medicine, National University of Singapore, Lower Kent Ridge Road, Singapore, 0511

Authors and Affiliations

  1. Department of Genetics and Microbiology, University of Geneva Medical School, 9, avenue de Champel, 1211, Geneva 4, Switzerland

    Hernan R. Chang MB, MD, Dr Med

Authors
  1. Hernan R. Chang MB, MD, Dr Med
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pure & Applied Biology, University of Leeds, LS2 9JT, Leeds, UK

    Judith E. Smith

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Chang, H.R. (1993). Toxoplasma Gondii: Chemotherapy. In: Smith, J.E. (eds) Toxoplasmosis. NATO ASI Series, vol 78. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78559-7_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78559-7_20

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-78561-0

  • Online ISBN: 978-3-642-78559-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation